These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18462248)

  • 1. The misuse of the faecal occult blood test under the lower gastrointestinal two week wait rule.
    Shaw AG; Lund JN; Longman C; Tierney GM; Goddard AF
    Colorectal Dis; 2009 Jan; 11(1):94-6. PubMed ID: 18462248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-week wait symptoms are prevalent in screened patients with a positive faecal occult blood test but do not predict cancer.
    Vaughan-Shaw PG; Cutting J; Borley N; Brooklyn T; Wheeler JM
    Colorectal Dis; 2014 Jan; 16(1):40-7. PubMed ID: 24103034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inappropriate use of the faecal occult blood test outside of the National Health Service colorectal cancer screening programme.
    Peacock O; Watts ES; Hanna N; Kerr K; Goddard AF; Lund JN
    Eur J Gastroenterol Hepatol; 2012 Nov; 24(11):1270-5. PubMed ID: 22872076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of faecal occult blood tests requested outside the UK National Bowel Cancer Screening Programme.
    McDonald R; Tomlins A; Smith S; Harmston C
    J Clin Pathol; 2013 Apr; 66(4):330-4. PubMed ID: 23288919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Referral of patients with iron deficiency anaemia under the lower gastrointestinal two-week wait rule.
    Shaw AG; Simpson J; Tierney G; Goddard AF; Reynolds JR; Lund JN
    Colorectal Dis; 2008 Mar; 10(3):294-7. PubMed ID: 17764534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunological faecal occult blood testing: a discriminatory test to identify colorectal cancer in symptomatic patients.
    Kaul A; Shah A; Magill FH; Hawkins SA; Skaife P
    Int J Surg; 2013; 11(4):329-31. PubMed ID: 23459187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An urgent referral strategy for symptomatic patients with suspected colorectal cancer based on a quantitative immunochemical faecal occult blood test.
    Rodríguez-Alonso L; Rodríguez-Moranta F; Ruiz-Cerulla A; Lobatón T; Arajol C; Binefa G; Moreno V; Guardiola J
    Dig Liver Dis; 2015 Sep; 47(9):797-804. PubMed ID: 26055489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptoms do not predict colorectal cancer in an FOB screened population.
    Saldanha JD; Moug SJ; Linton K; Diament RH
    Scott Med J; 2013 May; 58(2):95-8. PubMed ID: 23728754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based audit of the clinical use of faecal occult blood testing in primary care for colorectal cancer.
    Gillberg A; Ericsson E; Granstrom F; Olsson LI
    Colorectal Dis; 2012 Sep; 14(9):e539-46. PubMed ID: 22738077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review.
    Narula N; Ulic D; Al-Dabbagh R; Ibrahim A; Mansour M; Balion C; Marshall JK
    Can J Gastroenterol Hepatol; 2014 Sep; 28(8):421-6. PubMed ID: 25014182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How often is a positive faecal occult blood test the result of coeliac disease?
    Logan RF; Howarth GF; West J; Shepherd K; Robinson MH; Hardcastle JD
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1097-100. PubMed ID: 14501618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A New-Generation Fecal Immunochemical Test (FIT) Is Superior to Quaiac-based Test in Detecting Colorectal Neoplasia Among Colonoscopy Referral Patients.
    Vasilyev S; Smirnova E; Popov D; Semenov A; Eklund C; Hendolin P; Paloheimo L; Syrjänen K
    Anticancer Res; 2015 May; 35(5):2873-80. PubMed ID: 25964570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The two-week rule colorectal cancer pathway: an update on recent practice, the unsustainable burden on diagnostics and the role of faecal immunochemical testing.
    Maclean W; Singh R; Mackenzie P; White D; Benton S; Stebbing J; Rockall T; Jourdan I
    Ann R Coll Surg Engl; 2020 Apr; 102(4):308-311. PubMed ID: 32081023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 2-week wait referral system does not improve 5-year colorectal cancer survival.
    Zafar A; Mak T; Whinnie S; Chapman MA
    Colorectal Dis; 2012 Apr; 14(4):e177-80. PubMed ID: 21920007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.
    Hardcastle JD; Chamberlain JO; Robinson MH; Moss SM; Amar SS; Balfour TW; James PD; Mangham CM
    Lancet; 1996 Nov; 348(9040):1472-7. PubMed ID: 8942775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
    Clarke P; Jack F; Carey FA; Steele RJ
    Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screen-detected colorectal cancers show improved cancer-specific survival when compared with cancers diagnosed via the 2-week suspected colorectal cancer referral guidelines.
    Courtney ED; Chong D; Tighe R; Easterbrook JR; Stebbings WS; Hernon J
    Colorectal Dis; 2013 Feb; 15(2):177-82. PubMed ID: 22709315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2-week wait service: a UK tertiary colorectal centre's experience in the early identification of colorectal cancer.
    Patel RK; Sayers AE; Seedat S; Altayeb T; Hunter IA
    Eur J Gastroenterol Hepatol; 2014 Dec; 26(12):1408-14. PubMed ID: 25244412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of undetected ulcerative colitis: data from the Nottingham fecal occult blood screening trial.
    Howarth GF; Robinson MH; Jenkins D; Hardcastle JD; Logan RF
    Am J Gastroenterol; 2002 Mar; 97(3):690-4. PubMed ID: 11926210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of the addition of flexible sigmoidoscopy to faecal occult blood testing for colorectal neoplasia population screening.
    Berry DP; Clarke P; Hardcastle JD; Vellacott KD
    Br J Surg; 1997 Sep; 84(9):1274-6. PubMed ID: 9313712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.